Claims
- 1. A method of generating a mucosal immune response at a mucosal surface, said method comprising delivering a particulate vaccine composition into or across the skin of a vertebrate subject using a transdermal delivery technique, wherein the vaccine composition comprises an antigen or a nucleic acid encoding said antigen.
- 2. The method of claim 1 wherein the particulate vaccine composition is delivered using a needleless syringe powder injection device.
- 3. The method of claim 1 wherein the mucosal immune response is specific for the antigen.
- 4. The method of claim 3 wherein the mucosal immune response is characterized by an IgA antibody response specific for the antigen.
- 5. The method of claim 1 wherein the antigen is derived or obtained from a pathogen that enters a subject's body via a mucosal surface.
- 6. The method of claim 1 wherein the antigen is a viral antigen.
- 7. The method of claim 1 wherein the antigen is a bacterial antigen.
- 8. The method of claim 1 wherein the antigen is a live, attenuated organism.
- 9. The method of claim 1 further comprising the step of coadministering an adjuvant composition to the vertebrate subject.
- 10. The method of claim 9 wherein the adjuvant composition is particulate.
- 11. The method of claim 10 wherein the particulate adjuvant composition is delivered into or across the subject's skin using a transdermal delivery technique.
- 12. The method of claim 9 wherein the vaccine composition and the adjuvant composition are administered to the same site in the subject.
- 13. The method of claim 9 wherein the vaccine composition and the adjuvant composition are administered concurrently.
- 14. The method of claim 13 wherein the vaccine composition and the adjuvant composition are combined to provide a single composition.
- 15. The method of claim 14 wherein the vaccine composition is administered to the subject from a needleless syringe powder injection device.
- 16. The method of claim 9 wherein the mucosal immune response is specific for the antigen.
- 17. The method of claim 16 wherein the mucosal immune response is characterized by an IgA antibody response specific for the antigen.
- 18. The method of claim 0.9 wherein the antigen is derived or obtained from a pathogen that enters a subject's body via a mucosal surface.
- 19. The method of claim 9 wherein the adjuvant composition comprises an oligonucleotide containing a CpG motif.
- 20. The method of claim 9 wherein the adjuvant composition comprises an ADP-ribosylating toxin.
- 21. The method of claim 20 wherein the adjuvant composition comprises a cholera toxin.
- 22. The method of claim 9 wherein the adjuvant composition comprises a combination of two or more adjuvants.
- 23. The method of claim 22 wherein the adjuvant composition comprises a cholera toxin and an oligonucleotide containing a CpG motif.
- 24. A particulate vaccine composition suitable for delivery into or across skin of a vertebrate subject, said composition comprising:
(a) an antigen or a nucleic acid encoding said antigen; (b) an ADP-ribosylating toxin as an adjuvant; and (c) an oligonucleotide containing a CpG motif.
- 25. The vaccine composition of claim 24 wherein the ADP-ribosylating toxin is a cholera toxin.
- 26. The vaccine composition of claim 24 wherein the antigen is derived or obtained from a pathogen that enters a subject's body via a mucosal surface.
- 27. The vaccine composition of claim 24 wherein the antigen is a viral antigen.
- 28. The vaccine composition of claim 24 wherein the antigen is a bacterial antigen.
- 29. The vaccine composition of claim 24 wherein the antigen is a live, attenuated organism.
- 30. A method for treating or preventing a disease caused by the entry of a pathogen into the body of a vertebrate subject via a mucosal surface, said method comprising administering the vaccine composition of claim 26 to a subject in need of treatment or vaccination in an amount sufficient to bring about a mucosal immune response at a mucosal surface of the subject.
- 31. The method of claim 30 wherein the mucosal immune response is specific for the antigen.
- 32. The method of claim 30 wherein the vaccine composition is administered into or across the skin of the subject using a transdermal delivery technique.
- 33. The method of claim 32 wherein the vaccine composition is administered to the subject from a needleless syringe powder injection device.
- 34. A method for treating or preventing a disease caused by the entry of a pathogen into the body of a vertebrate subject via a mucosal surface, said method comprising:
(a) administering a particulate vaccine composition into or across skin of the subject, wherein the vaccine composition comprises an antigen derived or obtained from the pathogen, or a nucleic acid encoding said antigen; and (b) coadministering an adjuvant composition to the subject, wherein the adjuvant composition comprises an ADP-ribosylating toxin, and further wherein coadministration of the vaccine and aduvant compositions is sufficient to bring about a mucosal immune response spesific for the antigen.
- 35. The method of claim 34 wherein the ADP-ribosylating toxin is a cholera toxin.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is related to U.S. provisional application serial No. 60/164,529, filed Nov. 10, 1999, from which priority is claimed pursuant to 35 U.S.C. § 119(e)(1) and which application is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60164529 |
Nov 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09710104 |
Nov 2000 |
US |
Child |
10724727 |
Dec 2003 |
US |